Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H L Seewann

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim resultsH Ludwig, A M Cohen, H Huber, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 1999
Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphomaM A Fridrik, G Jäger, H R Kienzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trialM A Fridrik, H Hausmaninger, W Linkesch, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim resultsH Ludwig, A M Cohen, H Huber, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 1999
Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphomaM A Fridrik, G Jäger, H R Kienzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trialM A Fridrik, H Hausmaninger, W Linkesch, et al.
Pageof 4